Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SCRI Development Innovations, LLC
With
AstraZeneca
Pharmacia and Upjohn
Eli Lilly and Company
Upon determination of eligibility, all patients will be randomly assigned to one of two treatment arms:
* Paclitaxel + Carboplatin + Etoposide
* Irinotecan + Gemcitabine
Patients will be stratified by tumor location (liver/bone versus all others) and number of metastatic sites (one versus two or more). Patients with an objective response or stable disease after completion of chemotherapy will receive ZD1839 until disease progression. Patients who do not respond to chemotherapy may crossover to the other chemotherapy regimen and will receive ZD1839 if they have an objective response or stable disease. The study is not blinded so both the patient and the doctor will know which treatment has been assigned.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
To be included in this study, you must meet the following criteria:
Carcinoma of unknown primary site
Biopsy-proven metastatic carcinoma
Able to perform activities of daily living with minimal assistance
No previous treatment with any systemic therapy
Measurable or evaluable disease
Adequate bone marrow, liver and kidney function
Understand the nature of this study and give written informed consent
You may not be if
You cannot participate in this study if any of the following apply to you:
Age \< 18 years
Uncontrolled brain metastases and meningeal involvement
Other uncontrolled malignancies
Women pregnant or lactating
Recent history of significant cardiovascular disease
Severe or uncontrolled systemic disease
Other significant clinical disorder
Clinically active interstitial lung disease
Clareo Health | Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site
